TABLE 3.
Multivariable analysis of factors associated with clinical success at 30 days
| Factora | Treatment outcome |
P value | Multivariate P value (OR, 95% CI)a | |
|---|---|---|---|---|
| Success (n = 50) | Failure (n = 59) | |||
| Male (n [%]) | 26 (52) | 36 (61) | 0.34 | |
| Age (median [range]) | 59 (26–91) | 61 (25–85) | 0.49 | |
| Diabetes (n [%]) | 13 (26) | 22 (37) | 0.21 | |
| Chronic liver disease (n [%]) | 11 (22) | 20 (34) | 0.17 | |
| Chronic respiratory disease (n [%]) | 14 (28) | 12 (20) | 0.35 | |
| Immunocompromised (n [%]) | 25 (50) | 29 (49) | 0.93 | |
| Any malignancy (n [%]) | 7 (14) | 17 (29) | 0.06 | 0.10 |
| Solid-organ transplant recipient (n [%]) | 18 (36) | 22 (37) | 0.89 | |
| Primary bacteremia (n [%]) | 19 (38) | 9 (15) | 0.007 | 0.006 (4.50, 1.53–13.21) |
| Renal replacement therapy (n [%]) | 6 (12) | 18 (31) | 0.02 | 0.20 |
| Pitt bacteremia score (median [range]) | 3 (0–9) | 5 (0–9) | 0.003 | 0.15 |
| APACHE II score (median [range]) | 17 (7–38) | 21 (4–36) | 0.02 | Excluded for confounding |
| ICU (n [%]) | 21 (42) | 35 (59) | 0.07 | 0.24 |
| Treatment with ≥2 active agents (n [%]) | 21 (42) | 11 (19) | 0.008 | Excluded for confounding |
| Time to active treatment (median [IQR]) | 55.6 (23.5–74.6) | 66 (34.3–105) | 0.08 | 0.28 |
| Treatment with C-A (n [%]) | 11 (22) | 2 (3) | 0.003 | 0.01 (8.64, 1.61–46.39) |
a
CI, confidence interval; ICU, intensive care unit; IQR, interquartile range; OR, odds ratio.